Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
27 okt 2006 - 07:00
Statutaire naam
Pharming Group N.V.
Titel
PHARMING ANNOUNCES THIRD QUARTER 2006 RESULTS-Reports on solid cash position and progress in development of its products and technologies
Bericht
Leiden, The Netherlands, October 27, 2006. Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) today announced its results for the third quarter (Q3) ended September 30, 2006.
Key developments in the third quarter
Financial
? Cash position of € 36.5 million (including marketable securities) at September 30, 2006
? Total costs and expenses were € 4.1 million in Q3 2006 compared to € 4.0 million in Q3 2005 and
€ 4.4 million in Q2 2006
? Net loss of € 4.4 million in Q3 2006 compared to € 3.8 million in Q3 2005 and € 4.4 million in Q2 2006
? Total net loss of € 12.5 million in the first three quarters of 2006 compared to € 12.0 million in the first three quarters of 2005
? Inventories increased to € 8.3 million from € 7.7 million at June 30, 2006 in preparation for launch of Rhucin®
Products
? Marketing Authorization Application (MAA) for Rhucin® accepted for review by the European Medicines Agency (EMEA) for the treatment of acute attacks of hereditary angioedema (HAE)
? Discussion with regulatory authorities ongoing for the compassionate use of rhC1INH
? Fast Track designation on rhC1INH for the treatment of HAE from the US Food and Drug Administration (FDA)
? Orphan Drug designations for rhC1INH for treatment of two additional indications (Delayed Graft Function after solid organ transplantation and Capillary Leakage Syndrome) beyond HAE granted by the FDA
? Filing on human lactoferrin (hLF) for Generally Recognized as Safe (GRAS) notification under review with the FDA
Corporate
? Move to new Beagle building in Leiden's Bioscience Park
? Finalization of acquisition of DNage BV (“DNage”)
? Appointments of Dr. Rein Strijker as Chief Commercial Officer and Dr. Bruno Giannetti as Chief Operations Officer
“In the first nine months of 2006, Pharming strengthened its cash position through key transactions and well controlled costs and expenses,” said Dr. Francis J. Pinto, CEO of Pharming. “With the filing of the Marketing Au
Datum laatste update: 22 februari 2026